RxDoctor Payments Data

Sirisha Chada, MD

Family Medicine · Gardendale, ALNPI 1184061699

Payments from drug & device makers

$641in general payments, 2019–2025

Across 41 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$193
  • Boehringer Ingelheim$109
  • Pfizer$76
  • Amarin Pharma, Inc.$61
  • Novartis$46
  • Amgen$32
  • plus $124 from 8 others

What the payments were for

  • Food & beverage$641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$641 in reported general payments places this provider in the 45th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$58,551
Medicare patients
172
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$166,148
JardianceEmpagliflozin124$110,115
JanuviaSitagliptin Phosphate81$92,264
TrulicityDulaglutide70$86,614
MounjaroTirzepatide63$66,205
EliquisApixaban80$54,093
LinzessLinaclotide27$24,213
XareltoRivaroxaban19$22,121
Tresiba Flextouch U-200Insulin Degludec31$19,474
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$14,531
Lantus SolostarInsulin Glargine,hum.Rec.Anlog130$14,499
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,650
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$9,287
Atorvastatin Calcium753$9,264
FarxigaDapagliflozin Propanediol11$8,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$166,148136 claims
Boehringer IngelheimJardiance, Stiolto Respimat$109$119,403144 claims
MerckJanuvia, Belsomra$14$100,03399 claims
PfizerEliquis$76$54,09380 claims
AbbVieLinzess$193$24,21327 claims
Johnson & JohnsonXarelto$12$22,12119 claims
AstraZenecaFarxiga$13$8,95811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Gardendale

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →